Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation.

Authors: Sterclova, M  Vasakova, M  Pavlicek, J  Metlicka, M  Krasna, E  Striz, I 
Citation: Sterclova M, etal., Exp Lung Res. 2009 Aug;35(6):514-23.
Pubmed: (View Article at PubMed) PMID:19842835

Sarcoidosis and extrinsic allergic alveolitis (EAA) are granulomatous lung diseases with predominantly Th1 immune response. In this prospective study, the authors analyzed the expression of chemokine receptors CXCR2, CXCR3, and CCR3 on bronchoalveolar lavage fluid (BALF) CD4 T cells of patients either with EAA or sarcoidosis. The authors investigated the correlation of chemokine receptors expression, lymphocyte and neutrophil counts in BALF, and high-resolution tomography (HRCT) pattern. Thirteen sarcoidosis and 6 EAA patients were enrolled in the study. The expression of chemokine receptors on BALF CD4 T cells were analyzed by flow cytometry. HRCT scoring system according to Kazerooni was used for evaluation of the disease extent. The authors have found positive correlation between BALF CD4 T-cell CXCR3 expression and HRCT alveolar score in EAA patients (P <. 01). CXCR2 expression on BALF CD4 T cells and interstitial HRCT score did not show a correlation either in the EAA or the sarcoidosis group. Positive correlation between CCR3 expression on CD4+ T cells and HRCT interstitial score was proven in the EAA group (P <. 05). The authors conclude that Th2 predominant immune response may play an important role in chronic EAA pathogenesis. The role of chemokine receptors in the pathogenesis of EAA and sarcoidosis should be presumed and investigated.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 4145620
Created: 2010-11-10
Species: All species
Last Modified: 2010-11-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.